Drug Type Small molecule drug |
Synonyms VPI 013, VPI-013 |
Action antagonists, agonists |
Mechanism 5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), σ receptor agonists(Sigma receptors agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H32ClN3O5S |
InChIKeyLAYQZXHSBQXCFR-UHFFFAOYSA-N |
CAS Registry260369-93-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Phase 2 | - | - | |
Depressive Disorder | Phase 2 | - | - | |
Depressive Disorder, Major | Phase 2 | United States | - | |
Neuralgia | Phase 2 | - | - | |
Neuralgia | Phase 2 | - | - | |
Sexual Dysfunctions, Psychological | Phase 2 | - | - | |
Sexual Dysfunctions, Psychological | Phase 2 | - | - |